Benzinga | Apr 12, 2021 07:35AM EDT

Intra-Cellular Therapies Highlights Poster Presentation Of PDE1 Inhibitor Program At American Association for Cancer Research Virtual Annual Meeting

NEW YORK, April 12, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) today announced a poster presentation on its PDE1 inhibitor program at the ongoing 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting, which is being held from April 10 - 15, 2021. Details of the poster presentation are as follows:

Title Effects of ITI-214, a Potent and Selective Phosphodiesterase Type 1 Inhibitor, on Tumor Myeloid Cellular Composition, Tumor Volume and Survival in Mouse Models of Colorectal Cancer When Combined with an Anti-PD-1 Checkpoint Inhibitor (Poster 1243).

Session Category: Experimental and Molecular Therapeutics

Session Title: Novel Antitumor Agents